Estrogen promotes the metastasis of non‑small cell lung cancer via estrogen receptor β by upregulation of Toll‑like receptor 4 and activation of the myd88/NF‑κB/MMP2 pathway

Fan,Sheng; Liao,Yongde; Qiu,Wenlin; Huang,Quanfu; Xiao,Han; Liu,Changyu; Li,Dong; Cao,Xiaonian; Li,Lequn; Liang,Huifang; Ai,Bo; Zhou,Sheng

doi:10.3892/or.2020.7574

Estrogen promotes the metastasis of non‑small cell lung cancer via estrogen receptor β by upregulation of Toll‑like receptor 4 and activation of the myd88/NF‑κB/MMP2 pathway

Authors:
- Sheng Fan
- Yongde Liao
- Wenlin Qiu
- Quanfu Huang
- Han Xiao
- Changyu Liu
- Dong Li
- Xiaonian Cao
- Lequn Li
- Huifang Liang
- Bo Ai
- Sheng Zhou
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen University, Xiamen, Fujian 361000, P.R. China, Department of Thoracic Surgery, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China
Published online on: April 2, 2020 https://doi.org/10.3892/or.2020.7574
Pages: 2105-2119

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen promotes non‑small cell lung cancer (NSCLC) metastasis via estrogen receptor β (ERβ)‑mediated invasiveness‑associated matrix metalloprotease 2 (MMP2) upregulation. However, how ERβ increases the aggressiveness of NSCLC cells remains unclear. Recently, MMP2 was found to be upregulated by Toll‑like receptor 4 (TLR4) signaling activation and to promote NSCLC metastasis. Our present study aimed to examine the role of ERβ in the activation of TLR4 signaling and in tumor progression and metastasis, and to explore the synergistic metastatic effect of a combination of ERβ and TLR4 activation on human NSCLC cells in vitro and in vivo. Here, we found that ERβ is associated with TLR4 in metastatic lymph nodes. Western blot analysis and immunofluorescence revealed that ERβ overexpression upregulated TLR4 protein expression and activated downstream targets, myeloid differentiation primary response 88 (myd88)/nuclear factor (NF)‑κB/MMP2, enhancing NSCLC cell migration and invasion in vitro. A novel ERβ‑TLR4 interaction in cell plasma was identified by co‑immunoprecipitation and confocal immunofluorescence. The combination of estradiol and specific TLR4 agonist lipopolysaccharide (LPS) synergistically promoted metastatic behaviors in NSCLC cells. In cell culture and murine lung metastasis models, exposure to estradiol and LPS induced increased matrix degradation and accelerated invadopodia and metastasis formation in NSCLC cells compared with that in cells treated with estradiol or LPS alone. Together, we showed that estrogen promoted NSCLC metastasis via ERβ by upregulating TLR4 and activating its downstream signaling axis myd88/NF‑κB/MMP2. The combined targeting of ERβ and TLR4 may be a novel therapeutic strategy against advanced metastatic lung cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
2	Langer CJ, Besse B, Gualberto A, Brambilla E and Soria JC: The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol. 28:5311–5320. 2010. View Article : Google Scholar
3	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
4	Blaustein JD: Steroid hormone receptors: Long- and short-term integrators of the internal milieu and the external environment. Horm Metab Res. 44:563–568. 2012. View Article : Google Scholar
5	Nair S and Sachdeva G: Estrogen matters in metastasis. Steroids. 138:108–116. 2018. View Article : Google Scholar
6	Fan S, Liao Y, Liu C, Huang Q, Liang H, Ai B, Fu S and Zhou S: Estrogen promotes tumor metastasis via estrogen receptor beta-mediated regulation of matrix-metalloproteinase-2 in non-small cell lung cancer. Oncotarget. 8:56443–56459. 2017.
7	Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, et al Women's Health Initiative Investigators, : Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomised controlled trial. Lancet. 374:1243–1251. 2009. View Article : Google Scholar :
8	Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, et al: Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer. 123:91–98. 2018. View Article : Google Scholar :
9	Brown M and O'Reilly S: Innate immunity and Toll-like receptor signaling in the pathogenesis of scleroderma: Advances and opportunities for therapy. Curr Opin Rheumatol. 30:600–605. 2018. View Article : Google Scholar
10	Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell. 124:783–801. 2006. View Article : Google Scholar
11	Janeway CA Jr and Medzhitov R: Introduction: The role of innate immunity in the adaptive immune response. Semin Immunol. 10:349–350. 1998. View Article : Google Scholar
12	Bhattacharya D and Yusuf N: Expression of toll-like receptors on breast tumors: Taking a toll on tumor microenvironment. Int J Breast Cancer. 2012:7165642012. View Article : Google Scholar
13	Anthoney N, Foldi I and Hidalgo A: Toll and Toll-like receptor signalling in development. Development. 145:1452018. View Article : Google Scholar
14	Chow SC, Gowing SD, Cools-Lartigue JJ, Chen CB, Berube J, Yoon HW, Chan CH, Rousseau MC, Bourdeau F, Giannias B, et al: Gram negative bacteria increase non-small cell lung cancer metastasis via Toll-like receptor 4 activation and mitogen-activated protein kinase phosphorylation. Int J Cancer. 136:1341–1350. 2015. View Article : Google Scholar
15	Li D, Jin Y, Sun Y, Lei J and Liu C: Knockdown of toll-like receptor 4 inhibits human NSCLC cancer cell growth and inflammatory cytokine secretion in vitro and in vivo. Int J Oncol. 45:813–821. 2014. View Article : Google Scholar
16	Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D and Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 101:415–422. 2002. View Article : Google Scholar
17	Lv W, Chen N, Lin Y, Ma H, Ruan Y, Li Z, Li X, Pan X and Tian X: Macrophage migration inhibitory factor promotes breast cancer metastasis via activation of HMGB1/TLR4/NF kappa B axis. Cancer Lett. 375:245–255. 2016. View Article : Google Scholar
18	Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, et al IASLC Staging Prognostic Factors Committee, advisory boards, participating institutions, : The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol. 11:2112–2119. 2016. View Article : Google Scholar
19	Tang H, Liao Y, Xu L, Zhang C, Liu Z, Deng Y, Jiang Z, Fu S, Chen Z and Zhou S: Estrogen and insulin-like growth factor 1 synergistically promote the development of lung adenocarcinoma in mice. Int J Cancer. 133:2473–2482. 2013. View Article : Google Scholar
20	Huang Q, Zhang Z, Liao Y, Liu C, Fan S, Wei X, Ai B and Xiong J: 17β-estradiol upregulates IL6 expression through the ERβ pathway to promote lung adenocarcinoma progression. J Exp Clin Cancer Res. 37:1332018. View Article : Google Scholar :
21	Tang H, Liao Y, Chen G, Xu L, Zhang C, Ju S and Zhou S: Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β. Med Oncol. 29:2640–2648. 2012. View Article : Google Scholar
22	Liu C, Liao Y, Fan S, Tang H, Jiang Z, Zhou B, Xiong J, Zhou S, Zou M and Wang J: G protein-coupled estrogen receptor (GPER) mediates NSCLC progression induced by 17β-estradiol (E2) and selective agonist G1. Med Oncol. 32:1042015. View Article : Google Scholar
23	Hernandez H, Medina-Ortiz WE, Luan T, Clark AF and McDowell CM: Crosstalk between transforming growth factor beta-2 and Toll-like receptor 4 in the trabecular meshwork. Invest Ophthalmol Vis Sci. 58:1811–1823. 2017. View Article : Google Scholar :
24	Shaaban AA, El-Kashef DH, Hamed MF and El-Agamy DS: Protective effect of pristimerin against LPS-induced acute lung injury in mice. Int Immunopharmacol. 59:31–39. 2018. View Article : Google Scholar
25	Vinci M, Box C and Eccles SA: Three-dimensional (3D) tumor spheroid invasion assay. J Vis Exp. 99:e526862015.
26	Del Pozo JL: Primers on molecular pathways: Lipopolysaccharide signaling - potential role in pancreatitis and pancreatic cancer. Pancreatology. 10:114–118. 2010. View Article : Google Scholar
27	Siegfried JM and Stabile LP: Estrongenic steroid hormones in lung cancer. Semin Oncol. 41:5–16. 2014. View Article : Google Scholar
28	Matsunaga N, Tsuchimori N, Matsumoto T and Ii M: TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Mol Pharmacol. 79:34–41. 2011. View Article : Google Scholar
29	Thomas C and Gustafsson JA: The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 11:597–608. 2011. View Article : Google Scholar
30	Weaver AM: Invadopodia: Specialized cell structures for cancer invasion. Clin Exp Metastasis. 23:97–105. 2006. View Article : Google Scholar
31	Saykali BA and El-Sibai M: Invadopodia, regulation, and assembly in cancer cell invasion. Cell Commun Adhes. 21:207–212. 2014. View Article : Google Scholar
32	Goertzen CG, Dragan M, Turley E, Babwah AV and Bhattacharya M: KISS1R signaling promotes invadopodia formation in human breast cancer cell via β-arrestin2/ERK. Cell Signal. 28:165–176. 2016. View Article : Google Scholar
33	Kovats S: Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol. 294:63–69. 2015. View Article : Google Scholar :
34	Mai CW, Kang YB and Pichika MR: Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: Its expression and effects in the ten most common cancers. Onco Targets Ther. 6:1573–1587. 2013.
35	Rich AM, Hussaini HM, Parachuru VP and Seymour GJ: Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol. 5:4642014. View Article : Google Scholar :
36	Chiang AC and Massagué J: Molecular basis of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar :
37	Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A and Rathinavelu A: Matrix Metalloproteinases: A challenging paradigm of cancer management. Semin Cancer Biol. 56:100–115. 2019. View Article : Google Scholar
38	Brown GT and Murray GI: Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 237:273–281. 2015. View Article : Google Scholar
39	Prossnitz ER and Barton M: The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 7:715–726. 2011. View Article : Google Scholar :